Dermatologists are warning consumers that the harmless-looking, henna tattoos that are being sold everywhere from summer carnivals and open-air malls to cruise ships and vacation hot spots could contain a harmful chemical known as para-phenylenediamine, or PPD, used to create longer-lasting black henna tattoos. Notably, PPD has been associated with a rash of major skin problems.

At the American Academy of Dermatology’s Summer Academy Meeting 2008 in Chicago, dermatologist Sharon E. Jacob, MD, FAAD, assistant clinical professor of pediatrics and medicine (dermatology) at the University of California, San Diego, discussed the dangers of black henna tattoos and how dermatologists are treating an increasing number of patients, including very young children, with skin problems from allergic reactions to PPD.

Black Henna Tattoos

Natural henna used for temporary tattoos is made from leaves of the lawsonia inermis plant, which provides a vegetable coloring that comes in shades of brown, green or red. Temporary coloring (dyeing) of the skin with natural henna is considered harmless and only lasts for a few days. To increase the intensity of the tattoo beyond which can be attained with natural henna color and to prolong the longevity of the temporary tattoo from days to weeks, some henna tattoo artists are adding PPD (commonly also used for black hair dye) into the henna mix. This turns the tattoo black.

The U.S. Food and Drug Administration (FDA) prohibits the direct application of PPD to the skin because of its known health risks. However, since the tattoo industry is not regulated, people are still getting black henna tattoos and exposing themselves to serious medical problems.

“Perhaps the most alarming issue we are seeing with black henna tattoos is the increase in the number of children — even children as young as four — who are getting them and experiencing skin reactions,” said Dr. Jacob. “Kids make up a significant portion of the population that receives temporary tattoos, because parents mistakenly think they are safe since they are not permanent and are available at so many popular venues catering to families. In fact, nothing could be further from the truth.”

Dr. Jacob noted that to date, there have been hundreds of case reports of allergic contact dermatitis from black henna tattoos, with reactions ranging from mild eczema to blistering and even permanent scarring. The first sign of a reaction is typically redness and itching, followed by bumps, swelling and then blisters. Topical steroids can be used to stop the reaction, but Dr. Jacob explained that whether or not any scarring occurs depends on the depth and severity of the inflammation.

In addition, some people may become sensitized to PPD from just one exposure — meaning that the immune system becomes prepared to remember the chemical to which it has been exposed or a chemical with a similar structure. When this happens, a person can develop a lifelong sensitivity to PPD and an allergy can cause a cross reaction to other compounds, including certain medications. For example, use of some heart, hypertension and diabetes medications, and even some anesthetics used in topical hemorrhoid preparations or oral gels, can lead to allergic reactions in people previously sensitized to PPD.

“Each exposure to PPD re-challenges the immune system, so each time you get a black henna tattoo or use a hair dye that contains PPD, there is an increased risk of having a reaction,” said Dr. Jacob. “Many people are sensitized to PPD, but don’t have a reaction to it. However, each time you are exposed to black henna, you increase your risk of developing a lifelong allergy to it.”

Dr. Jacob advised if one does choose to obtain a henna tattoo, only do so if you can be certain that only vegetable henna is used, not PPD-adulterated henna. “Unless the artist can tell you exactly what’s in the tattoo, don’t get one,” said Dr. Jacob.

The American Academy of Dermatology Association (AADA) endorses a ban on the practice of applying PPD-adulterated henna tattoos, and some state dermatology societies have started posting warnings on their Web sites about black henna tattoos.

For any skin reactions that develop from a temporary tattoo, Dr. Jacob recommended that people see their dermatologist for proper diagnosis and treatment. If a serious reaction occurs, such as severe blistering or swelling, she said seek immediate medical attention.

Source: American Academy of Dermatology


National Medical Association Installs 109th President at Atlanta Convention

  • Author: Health Informer
  • Filed under: Health News
  • Date: Jul 31,2008

New NMA President to Address Cancer and Mental Health Disparities

Delivering her inaugural address as the 109th president of the National Medical Association (NMA), Carolyn Barley Britton, M.D., M.S., shared her plans to focus on cancer and mental health disparities during her administration. The NMA is the nation’s premier organization for African American physicians.

Dr. Britton, a recognized expert in neurovirology and infectious/inflammatory diseases of the nervous system, is currently associate professor of Clinical Neurology at Columbia University College of Physicians and Surgeons, and associate attending physician at New York Presbyterian Hospital in New York, NY.

A native of Huntsville, Alabama, Britton is a graduate of Oberlin College and New York University Medical School, where she received her M.S. in Microbiology (Virology) and her M.D.

For more than 20 years, Dr. Britton has worked to support funding for AIDS clinical trials. Her work at the National Institute of Allergy and Infectious Diseases (NIAID) influenced federal clinical research guidelines to require inclusion of women and minorities, and to expand clinical trials in the African American community. Among the first to describe the neurologic complications of AIDS, Britton is an authority on a rare viral complication, progressive multifocal leukoencephalopathy.

Dr. Britton’s work in the National Medical Association includes leadership positions from the local to the national level. She has served as President of the Manhattan Medical Society; Chair, Neurology/Neurosurgery Section of the NMA and Chair of Board of Trustees.

“This year, as we build on the outstanding work of our immediate past presidents in the areas of obesity, diabetes and HIV/AIDS, we will also bring disparities in cancer and mental health to the forefront of our agenda.” said Dr. Britton. In partnership with American Cancer Society, the NMA plans to launch national efforts to reduce cancer disparities. “We will also continue to build bridges to universal health care,” declared Dr. Britton.

“Dr. Britton has built an enviable record of impact in every leadership position at the NMA,” said Dr. Nedra H. Joyner. “We look forward to her service and guidance as President; it’s an exciting time for our organization.”

More than 3,000 physicians representing 25 specialties attended the weeklong convention that featured presentations by numerous medical experts, policy makers and industry leaders. Convention participants and luminaries included former Surgeon General David Satcher, M.D., Ph.D.; Democratic Committee Chair, Howard Dean, M.D.; Acclaimed Actress, Phylicia Rashad; Former Health and Human Services Secretary, Louis Sullivan, M.D; Mayor Shirley Franklin; and football superstar, Jerome Bettis.

Source: National Medical Association


Survey Paints Bleak Picture of Funding for Continence Care Services

  • Author: Health Informer
  • Filed under: Health News
  • Date: Jul 29,2008

A recent AHPMA survey among continence care professionals has painted a bleak picture on the current state of many continence services in the UK, largely due to lack of Government funding. The survey finds that continence care staff are striving for quality care within extremely limited resources.

The survey received 148 responses, which show an unacceptably low level of funding in many Primary Care Trusts; morale being lower than five years ago in over half of Trusts; increased workloads and vacancies not being filled. It demonstrates a wide variance in Continence Services and shows little evidence that the ‘Good practice in continence services’ document published by the Department of Health in 2000 has been considered by Trusts.

Two fifths of respondents say that waiting times for assessment and provision of products are increasing, several months not being unusual, and one Trust actually reporting waiting times of over 12 months.

Responses indicated that around half of Trusts exclude certain patients groups from receiving products, for example one group listed is those with ‘light urinary incontinence’ but without defining what volume of urinary loss is considered ‘light’ as opposed to ‘medium’ or ‘heavy.’ Patient choice is also found to be restricted.

Quality continence services and products are essential for patients and carers alike. Regular assessment and correct products are vital for quality of life, independence and health. Given the prevalence of this condition across all age groups but predominantly among the older population and other vulnerable groups, AHPMA would encourage a radical review of Continence Services at Government level, with strategic planning for increased demands on the services due to an ageing population, and mandatory targets for trusts.

AHPMA is the trade association which represents key UK manufacturers of absorbent disposable continence care products. To review the full survey visit HTTP://www.ahpma.co.uk or contact AHPMA on +44-(0)1483-418312 to receive a copy.

Incontinence is more prevalent than asthma, epilepsy and dementia. Currently 4-6 million people will suffer from some form of incontinence in the UK which affects men, women and children, for a wide variety of reasons. It is also a ‘taboo’ subject preventing many people from seeking help to a problem that can often be improved and in many cases cured which would save the NHS money in the long term.

Facts:

  • 4-6 million people in the UK will suffer from some form of incontinence – 6% of the population
  • Incontinence can mean anything from an occasional light involuntary leakage of urine, to moderate or heavy leakage and/or loss of bowel control. This condition may be temporary or long term depending on its cause and treatment.
  • Incontinence is more prevalent than asthma, epilepsy and dementia
  • Around only one in four people who suffer urinary incontinence seek help – 85% could possibly be cured* (*Royal College of Physicians 2005)
  • Incontinence is often the main reason why people move into residential care homes
  • The average increase of incontinent clients per NHS Trust is 8% per annum, many with increasing dependency costs
  • 3,680,000 people self fund purchasing of absorbent continence products at home.
  • The Government had a mandatory target to deliver integrated incontinence services by April 2004. In December 2006, the Royal College of Physicians survey indicated that integrated services are “still a dream rather than a reality”
  • Integrated Continence Services was a recommendation from the DoH in 2000, but have been developed in only in only 53 out of 138 Primary Care Sites.
  • AHPMA members are: Abena UK Ltd, Arquest Ltd, Attends Ltd, Johnson & Johnson GmbH, Kimberly-Clark Ltd, Lille Healthcare Ltd, Lil-lets (UK) Ltd, Multibrands International Ltd, Ontex Retail UK Ltd, Playtex Products Inc, Procter & Gamble UK, SCA Hygiene Products Ltd, Paul Hartmann Ltd, Toiletry Sales Ltd.

Source: AHPMA


Riverside Partners Teams with Management to Acquire HealthDrive

  • Author: Health Informer
  • Filed under: Health News
  • Date: Jul 29,2008

Riverside Partners, based in Boston, MA, is pleased to announce that it has partnered with management to acquire HealthDrive (“HealthDrive” or the “Company”).

HealthDrive is the leading provider of multi-specialty, on-site healthcare services to residents of extended care facilities. HealthDrive’s multi modality business model brings top quality dentistry, optometry, podiatry and audiology services directly to residents in over 900 facilities in nine states. In addition to clinical services across multiple specialties, HealthDrive provides geriatric-specific products to its patients, including eyeglasses, hearing aids, dentures and podiatry products. HealthDrive is headquartered in Newton, MA.

“Riverside is a big believer in bringing high-quality healthcare services to patients in the convenient setting of their own facility. HealthDrive’s differentiated business model provides a wide range of highly valuable services to patients and to its extended care facility partners. The management team has positioned the Company for significant future growth and we are excited to be partnering with them,” said David Belluck, General Partner at Riverside.

“We were looking for a partner who could bring more than capital to the company. Riverside’s operating and investment experience in the healthcare industry combined with the firm’s proven track record of growing middle market companies made them a perfect partner for us,” said Steven Charlap, M.D., CEO of HealthDrive.

About HealthDrive

Founded in 1989, HealthDrive provides mobile health and dental services to geriatric patients in extended care facilities. Headquartered in Newton, MA, HealthDrive not only provides dentistry, optometry, podiatry and audiology services but also offers geriatric-specific products to its patients.

About Riverside Partners

Founded in 1989, Riverside Partners is a middle market private equity firm currently investing Riverside Fund III, L.P. The fund focuses on growth- oriented companies in the healthcare and technology industries. Riverside is particularly experienced at partnering with founders, owners and management teams and it brings substantial domain expertise and operating experience to its portfolio companies. The partners at Riverside have managed more than $500 million in investments in over 50 companies. We are currently focused on companies with revenues between $20 – $200 million and with $5 – $25 million of EBITDA.

Source: Riverside Partners